entertainment -WSS

entertainment

author：Wikipedia 2025-09-06 03:54:49 - browse：79149

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Was Amgen transparent enough on FDA's concern on cancer drug?

leisure time

WSS

Physician executives need more than on

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

CVS Caremark has created a new ploy: the drug ‘rebate credit’

A Q&A with the global head of Boehringer Ingelheim's innovation unit

The future of health care in the House

Leading voice in opioid treatment defends methadone clinic system

hotspot

entertainment

hotspot

New air purifier tech could be key to improving indoor air quality

App could help diagnose ear infections more accurately — and at home

Walensky prepares to leave CDC — and Congress — behind

Stroke deaths set to near 10 million globally by 2050

Heart attack and stroke risk calculators need revising

FDA panel signals lack of confidence in Amgen cancer drug data

Alkermes shareholders re

Was Amgen transparent enough on FDA's concern on cancer drug?

Drug repurposing or repositioning? The language matters

5 to watch: Tech startups trying to solve health care's staffing crisis

explore

Phenylephrine and the overlooked value of the placebo effect

Physicians and social media: If you see something, say something?

Stroke deaths set to near 10 million globally by 2050

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

3 questions for the future of Biden's cancer moonshot

FDA authorizes Novavax’s updated Covid

explore

leisure time

knowledge

focus